Results 191 to 200 of about 3,449 (222)

Alloimmunization and Platelet Transfusion Refractoriness

1993
Since over 20 years platelet transfusions are established therapy allowing prolonged survival of patients with hematologic and hemato-oncologic diseases.
openaire   +1 more source

Diagnosis and management of refractoriness to platelet transfusion

Blood Reviews, 2001
Improvements in the availability and quality of platelet transfusions have markedly reduced the morbidity and mortality associated with intensive myelosuppressive therapy. Alloimmunization and refractoriness to platelet transfusion remains a significant clinical problem, although the incidence of alloimmunization may be declining due to more widespread
openaire   +2 more sources

Complement as an Immune Barrier in Platelet Transfusion Refractoriness

Transfusion Medicine Reviews, 2019
Patients with hematological cancers often have low platelet counts because of progressing bone marrow failure or cytostatic therapy. A large fraction of those patients need platelet transfusions, which can be life-saving if bleedings occur and also allow diagnostic and therapeutic interventions. The outcomes of platelet transfusions are not always easy
Stephan, Meinke, Cecilia, Karlström, Petter, Höglund   +2 more
openaire   +2 more sources

ABO non‐identical platelet transfusions, immune platelet refractoriness and platelet support

British Journal of Haematology
SummaryABO‐non‐identical (ABO‐ni) platelets may be another risk factor for immune platelet transfusion refractoriness (i‐PTR). We examined the effect of such platelets on i‐PTR and subsequent platelet support through retrospective analysis of 17 322 New Zealand patients receiving ≥1 platelets.
Min‐Hi Han, Krishna Govind Badami
openaire   +2 more sources

Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management

Blood Reviews, 2023
Sandhya R Panch
exaly  

Strategies for managing refractoriness to platelet transfusions.

Current hematology reports, 2003
The availability of platelet transfusions made possible intensive, myelosuppressive therapy. Chronic transfusion support is often complicated by refractoriness to platelet transfusions characterized by inadequate post-transfusion platelet count increments. Refractoriness is most commonly associated with a variety of clinical factors.
Maria E, Dan, Charles A, Schiffer
openaire   +1 more source

Refractoriness to Platelet Transfusions

American Journal of Clinical Pathology, 1989
openaire   +2 more sources

Platelet Transfusion Refractoriness: Controversial Issues

Clinical Medicine Review, 2018
Javier Marco, Pilar Solves
openaire   +1 more source

Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases

Platelets, 2023
Yue Han
exaly  

Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion

Transfusion Medicine Reviews, 2020
Roger Belizaire
exaly